Akari Therapeutics announced the appointment of experienced life sciences executive Wendy DiCicco as interim Chief Financial Officer, CFO. DiCicco has more than 25 years of experience in the life sciences industry, currently serving as an independent financial and board advisor to companies, often in the role of interim CFO. DiCicco served as CFO for Renovacor, a pre-clinical biopharmaceutical company developing a gene therapy for cardiovascular disease.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AKTX:
- Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer
- Akari Therapeutics provides updates on development of nomacopan for HSCT-TMA
- Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy
- Akari Therapeutics provides update on development of long-acting PAS-nomacopan
- Akari Therapeutics receives positive opinion from EMA on nomacopan designation
